Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Opus Genetics's Revenue for the
three
months ended in Jun. 2026 was €0.66 Mil. Opus Genetics's average Accounts Receivable for the
three
months ended in Jun. 2026 was €1.20 Mil.
Hence, Opus Genetics's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.55.
Opus Genetics (FRA:R3X1) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Opus Genetics Receivables Turnover Related Terms
Opus Genetics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R3X1 vs TTRX, VRXA, IFRX: Receivables Turnover Comparison
For the Biotechnology subindustry, Opus Genetics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (FRA:R3X1) has a Receivables Turnover of 0.55 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #489 out of 843 companies in the Biotechnology industry, placing it in the top 58%.
Is Opus Genetics' Receivables Turnover too high?
Opus Genetics' current Receivables Turnover is 0.55. The Biotechnology industry median Receivables Turnover is 5.27. Opus Genetics' value of 0.55 is 89.6% below this industry median. Based on the distribution chart, Opus Genetics ranks #489 out of 843 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Receivables Turnover compare to TTRX and VRXA?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #489 out of 843 companies for Receivables Turnover. This places Opus Genetics in the lower half of its industry. The industry median Receivables Turnover is 5.27. Opus Genetics' value of 0.55 is 89.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current Receivables Turnover of 0.55 is 89.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Opus Genetics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current Receivables Turnover is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (FRA:R3X1) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.25, compared to a current price of €3.20 — trading 1180% above its estimated fair value. The current Receivables Turnover is 0.55 and 89.6% below the Biotechnology industry median of 5.27. Opus Genetics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Opus Genetics (FRA:R3X1), the current Receivables Turnover is 0.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (FRA:R3X1) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of €3.20 is trading 1180% above its estimated GF Value™ of €0.25.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for FRA:R3X1:
Receivables Turnover: 0.55
GF Value™: €0.25 vs. price of €3.20 (1180% above fair value)
Industry Position: 89.6% below the Biotechnology median (#489 of 843)
No single metric tells the full story. See the FRA:R3X1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score
Get the complete analysis for FRA:R3X1
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R3X1 has been successfully added to your 
